Search

Your search keyword '"Cardenal, Felipe"' showing total 33 results
Start Over Author "Cardenal, Felipe" Search Limiters Full Text
33 results on '"Cardenal, Felipe"'

1. European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database

Author

Stahel, Rolf, Hiltbrunner, Anita, Kammler, Rosita, Marti, Nesa, Ruepp, Barbara, Dafni, Urania, Tsourti, Zoi, Zygoura, Panagiota, Vervita, Katerina, Dimopoulou, Georgia, Andriakopoulou, Charitini, Stavrou, Androniki, Rüschoff, Jan H., Haberecker, Martina, Dettwiler, Susanne, Prutek, Fabiola, Mittmann, Christiane, Opitz, Isabelle, Vrugt, Bart, Friess, Martina, Matter, Alessandra, Spichiger-Häusermann, Chloé, Kirschner, Michaela B., Felley-Bosco, Emanuela, Baas, Paul, Monkhorst, Kim, Nackaerts, Kristiaan, Verbeken, Eric, Weynand, Birgit, Nafteux, Philippe, Moons, Johnny, Peeters, Liesbet, Ampollini, Luca, Tiseo, Marcello, Silini, Enrico Maria, Gnetti, Letizia, Carbognani, Paolo, de Perrot, Marc, Bavaghar-Zaeimi, Fatemeh, Brcic, Luka, Samarzija, Miroslav, Seiwerth, Sven, Jakopovic, Marko, Nadal, Ernest, Cardenal, Felipe, Llatjos, Roger, Lorente, Susana, Syrigos, Konstantinos, Vamvakaris, Ioannis, Tsimpoukis, Sotirios, Boura, Paraskevi, Gray, Steven G., Finn, Stephen P., Nur, Mutaz Mohammed, Baird, Anne-Marie, Barr, Martin P., Cuffe, Sinead, Gately, Kathy, Aerts, Joachim, Thüsen, Jan von der, Bille, Andrea, Passani, Stefano, Brunelli, Alessandro, Curioni-Fontecedro, Alessandra, von der Thüsen, Jan, Kammler, Roswitha, Peters, Solange, Stahel, Rolf A., and Falcoz, Pierre-Emmanuel

Published
2023
Full Text
View/download PDF

2. Expression of phosphorylated ribosomal protein S6 in mesothelioma patients - correlation with clinico-pathological characteristics and outcome: results from the European Thoracic Oncology Platform (ETOP) Mesoscape project

Author

Rüschoff, Jan Hendrik, Haberecker, Martina, Tsourti, Zoi, Nackaerts, Kristiaan, de Perrot, Marc, Brcic, Luka, Nadal, Ernest, Tsimpoukis, Sotirios, Gray, Steven G., Ampollini, Luca, Aerts, Joachim G., Felley-Bosco, Emanuela, Kirschner, Michaela B., Monkhorst, Kim, Weynand, Birgit, Bavaghar-Zaeimi, Fatemeh, Samarzija, Miroslav, Llatjos, Roger, Finn, Stephen P., Silini, Enrico, von der Thüsen, Jan, Marti, Nesa, Vervita, Karerina, Kammler, Roswitha, Peters, Solange, Stahel, Rolf A., Baas, Paul, Opitz, Isabelle, Stahel, Rolf, Hiltbrunner, Anita, Kammler, Rosita, Vagenknecht, Patrick, Ruepp, Barbara, Dafni, Urania, Zygoura, Panagiota, Vervita, Katerina, Dimopoulou, Georgia, Andriakopoulou, Charitini, Stavrou, Androniki, Rüschoff, Jan H., Dettwiler, Susanne, Prutek, Fabiola, Mittmann, Christiane, Vrugt, Bart, Friess, Martina, Matter, Alessandra, Spichiger-Häusermann, Chloé, Verbeken, Eric, Weyenand, Birgit, Peeters, Liesbet, Tiseo, Marcello, Silini, Enrico Maria, Ventura, Luigi, Gnetti, Letizia, Carbognani, Paolo, Zaeimi, Fatemeh B., Seiwerth, Sven, Jakopovic, Marko, Cardenal, Felipe, Lorente, Susana, Syrigos, Konstantinos, Vamvakaris, Ioannis, Boura, Paraskevi, Gray, Steven, Nur, Mutaz Mohammed, Baird, Anne-Marie, Barr, Martin, Cuffe, Sinead, Gately, Kathy, and Aerts, Joachim

Published
2022
Full Text
View/download PDF

4. European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database

Author

Opitz, Isabelle, primary, Bille, Andrea, additional, Dafni, Urania, additional, Nackaerts, Kristiaan, additional, Ampollini, Luca, additional, de Perrot, Marc, additional, Brcic, Luka, additional, Nadal, Ernest, additional, Syrigos, Konstantinos, additional, Gray, Steven G., additional, Aerts, Joachim, additional, Curioni-Fontecedro, Alessandra, additional, Rüschoff, Jan H., additional, Monkhorst, Kim, additional, Weynand, Birgit, additional, Silini, Enrico Maria, additional, Bavaghar-Zaeimi, Fatemeh, additional, Jakopovic, Marko, additional, Llatjos, Roger, additional, Tsimpoukis, Sotirios, additional, Finn, Stephen P., additional, von der Thüsen, Jan, additional, Marti, Nesa, additional, Dimopoulou, Georgia, additional, Kammler, Roswitha, additional, Peters, Solange, additional, Stahel, Rolf A., additional, Falcoz, Pierre-Emmanuel, additional, Brunelli, Alessandro, additional, Baas, Paul, additional, Stahel, Rolf, additional, Hiltbrunner, Anita, additional, Kammler, Rosita, additional, Ruepp, Barbara, additional, Tsourti, Zoi, additional, Zygoura, Panagiota, additional, Vervita, Katerina, additional, Andriakopoulou, Charitini, additional, Stavrou, Androniki, additional, Haberecker, Martina, additional, Dettwiler, Susanne, additional, Prutek, Fabiola, additional, Mittmann, Christiane, additional, Opitz, Isabelle, additional, Vrugt, Bart, additional, Friess, Martina, additional, Matter, Alessandra, additional, Spichiger-Häusermann, Chloé, additional, Kirschner, Michaela B., additional, Felley-Bosco, Emanuela, additional, Verbeken, Eric, additional, Nafteux, Philippe, additional, Moons, Johnny, additional, Peeters, Liesbet, additional, Tiseo, Marcello, additional, Gnetti, Letizia, additional, Carbognani, Paolo, additional, Samarzija, Miroslav, additional, Seiwerth, Sven, additional, Cardenal, Felipe, additional, Lorente, Susana, additional, Vamvakaris, Ioannis, additional, Boura, Paraskevi, additional, Nur, Mutaz Mohammed, additional, Baird, Anne-Marie, additional, Barr, Martin P., additional, Cuffe, Sinead, additional, Gately, Kathy, additional, Thüsen, Jan von der, additional, and Passani, Stefano, additional

Published
2023
Full Text
View/download PDF

9. Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin

Author

Karp, Daniel D., Pollak, Michael N., Cohen, Roger B., Eisenberg, Peter D., Haluska, Paul, Yin, Donghua, Lipton, Allan, Demers, Laurence, Leitzel, Kim, Hixon, Mary L., Terstappen, Leon W., Garland, Linda, Paz-Ares, Luis G., Cardenal, Felipe, Langer, Corey J., and Gualberto, Antonio

Published
2009
Full Text
View/download PDF

13. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer

Author

Rosenfeld, Myrna R., Malats, Nuria, Schramm, Laura, Graus, Francesc, Cardenal, Felipe, Vinolas, Nuria, Rosell, Rafael, Tora, Montserrat, Real, Francisco X., Posner, Jerome B., and Dalmau, Josep

Subjects
Lung cancer, Small cell -- Prognosis, Tumor suppressor genes -- Physiological aspects, Gene mutations -- Physiological aspects, Health
Abstract

Background: Some patients with cancer develop antibodies against the p53 tumor suppressor protein. The presence of these antibodies in serum has been associated with the expression of mutant p53 by the tumor and in some studies with a poorer survival. Purpose: The goals of this study were to determine the prevalence of anti-p53 anti-bodies in the serum of patients with newly diagnosed small-cell lung cancer (SCLC) and to assess the clinical relevance of the presence of these antibodies in the serum, particularly their relationship with tumor response to treatment and with patient survival. Methods: In this prospective study, serum was obtained from 170 patients at the time of diagnosis of SCLC who were to subsequently receive platinumor doxorubicin-based chemotherapy at any one of four hospitals in Barcelona, Spain, from October 1991 through June 1994. Normal human sera from blood bank donors (n = 50) served as controls. The presence of anti-p53 antibodies was determined by western blot analysis with the use of purified recombinant p53 protein. As of January 1996, 96.5% of the patients had been treated and observed in the study, for a median follow-up time of 33.5 months. Survival was estimated by the Kaplan-Meier method. Cox proportional hazards regression and unconditional logistic regression analyses were conducted. All P values resulted from two-sided tests. Results: Anti-p53 antibodies were detected in the serum of 27 (16%) of the 170 patients studied. None of 50 serum samples from normal individuals contained anti-p53 antibodies. Analysis of pretreatment clinical characteristics demonstrated that a weight loss of less than 5% (P = .025), a serum lactic acid dehydrogenase (LDH) level of less than 450 U/L (P = .002), and limited stage disease (i.e., tumor confined to one hemithorax, with local and regional lymph node positivity for tumor cells and/or ipsilateral pleural effusion allowed) (P [is less than] .001]) were associated with a statistically significant complete response to therapy. The presence of serum anti-p53 antibodies was not associated with clinical characteristies, such as age (P = .622), functional status (P = 1.0), disease stage (P = .634), complete response to treatment (P = .572), and survival (P = .492) or with any laboratory parameters including known prognostic factors in SCLC, such as serum sodium or LDH concentration (P values of .731 and .246, respectively). Conclusions and Implications: The presence of anti-p53 antibodies in the serum of patients with newly diagnosed SCLC was not associated with any clinical characteristics or prognostic markers, suggesting that, in this context, the measurement of anti-p53 antibodies is not a useful prognostic marker. [J Natl Cancer Inst 1997; 89:381-5]

Published
1997

14. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT) : an open-label, phase 3, randomised, superiority trial

Author

Faivre-Finn, Corinne, Snee, Michael, Ashcroft, Linda, Appel, Wiebke, Barlesi, Fabrice, Bhatnagar, Adityanarayan, Bezjak, Andrea, Cardenal, Felipe, Fournel, Pierre, Harden, Susan, Le Pechoux, Cecile, McMenemin, Rhona, Mohammed, Nazia, O'Brien, Mary, Pantarotto, Jason, Surmont, Veerle, van Meerbeeck, Jan, Woll, Lorigan, Paul, Blackhall, Fiona, and Woll, Penella J.

Subjects
Human medicine
Abstract

Background Concurrent chemoradiotherapy is the standard of care in limited-stage small-cell lung cancer, but the optimal radiotherapy schedule and dose remains controversial. The aim of this study was to establish a standard chemoradiotherapy treatment regimen in limited-stage small-cell lung cancer. Methods The CONVERT trial was an open-label, phase 3, randomised superiority trial. We enrolled adult patients (aged ≥18 years) who had cytologically or histologically confirmed limited-stage small-cell lung cancer, Eastern Cooperative Oncology Group performance status of 02, and adequate pulmonary function. Patients were recruited from 73 centres in eight countries. Patients were randomly assigned to receive either 45 Gy radiotherapy in 30 twice-daily fractions of 1·5 Gy over 19 days, or 66 Gy in 33 once-daily fractions of 2 Gy over 45 days, starting on day 22 after commencing cisplatinetoposide chemotherapy (given as four to six cycles every 3 weeks in both groups). The allocation method used was minimisation with a random element, stratified by institution, planned number of chemotherapy cycles, and performance status. Treatment group assignments were not masked. The primary endpoint was overall survival, defined as time from randomisation until death from any cause, analysed by modified intention-to-treat. A 12% higher overall survival at 2 years in the once-daily group versus the twice-daily group was considered to be clinically significant to show superiority of the once-daily regimen. The study is registered with ClinicalTrials.gov (NCT00433563) and is currently in follow-up. Findings Between April 7, 2008, and Nov 29, 2013, 547 patients were enrolled and randomly assigned to receive twice-daily concurrent chemoradiotherapy (274 patients) or once-daily concurrent chemoradiotherapy (273 patients). Four patients (one in the twice-daily group and three in the once-daily group) did not return their case report forms and were lost to follow-up; these patients were not included in our analyses. At a median follow-up of 45 months (IQR 3558), median overall survival was 30 months (95% CI 2434) in the twice-daily group versus 25 months (2131) in the once-daily group (hazard ratio for death in the once daily group 1·18 [95% CI 0·951·45]; p=0·14). 2-year overall survival was 56% (95% CI 5062) in the twice-daily group and 51% (4557) in the once-daily group (absolute difference between the treatment groups 5·3% [95% CI −3·2% to 13·7%]). The most common grade 34 adverse event in patients evaluated for chemotherapy toxicity was neutropenia (197 [74%] of 266 patients in the twice-daily group vs 170 [65%] of 263 in the once-daily group). Most toxicities were similar between the groups, except there was significantly more grade 4 neutropenia with twice-daily radiotherapy (129 [49%] vs 101 [38%]; p=0·05). In patients assessed for radiotherapy toxicity, was no difference in grade 34 oesophagitis between the groups (47 [19%] of 254 patients in the twice-daily group vs 47 [19%] of 246 in the once-daily group; p=0·85) and grade 34 radiation pneumonitis (4 [3%] of 254 vs 4 [2%] of 246; p=0·70). 11 patients died from treatment-related causes (three in the twice-daily group and eight in the once-daily group). Interpretation Survival outcomes did not differ between twice-daily and once-daily concurrent chemoradiotherapy in patients with limited-stage small-cell lung cancer, and toxicity was similar and lower than expected with both regimens. Since the trial was designed to show superiority of once-daily radiotherapy and was not powered to show equivalence, the implication is that twice-daily radiotherapy should continue to be considered the standard of care in this setting.

Published
2017

15. Protocol for the CONVERT trial-Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status

Author

Faivre-Finn, Corinne, Falk, Sally, Ashcroft, Linda, Bewley, Michelle, Lorigan, Paul, Wilson, Elena, Groom, Nicki, Snee, Michael, Fournel, Pierre, Cardenal, Felipe, Bezjak, Andrea, and Blackhall, Fiona

Subjects
Adult, Male, Lung Neoplasms, Adolescent, Young Adult, Clinical Protocols, Protocol, Humans, Prospective Studies, Aged, Neoplasm Staging, Aged, 80 and over, Dose-Response Relationship, Radiation, Chemoradiotherapy, CHEMOTHERAPY, Middle Aged, Small Cell Lung Carcinoma, Survival Analysis, Treatment Outcome, Oncology, Female, Dose Fractionation, Radiation
Abstract

Introduction Concurrent ONce-daily VErsus twice-daily RadioTherapy (CONVERT) is the only multicentre, international, randomised, phase III trial open in Europe and Canada looking at optimisation of chemoradiotherapy (RT) in limited stage small cell lung cancer (LS-SCLC). Following on from the Turrisi trial of once-daily versus twice-daily (BD) concurrent chemoradiotherapy, there is a real need for a new phase III trial using modern conformal RT techniques and investigating higher once-daily radiation dose. This trial has the potential to define a new standard chemo-RT regimen for patients with LS-SCLC and good performance status.Methods and analysis 447 patients with histologically or cytologically proven diagnosis of SCLC were recruited from 74 centres in eight countries between 2008 and 2013. Patients were randomised to receive either concurrent twice-daily RT(45 Gy in 30 twice-daily fractions over 3 weeks) or concurrent once-daily RT(66 Gy in 33 once-daily fractions over 6.5 weeks) both starting on day 22 of cycle 1. Patients are followed up until death. The primary end point of the study is overall survival and secondary end points include local progression-free survival, metastasis-free survival, acute and late toxicity based on the Common Terminology Criteria for Adverse Events V.3.0, chemotherapy and RTdose intensity.Ethics and dissemination The trial received ethical approval from NRES Committee North West—Greater Manchester Central (07/H1008/229). There is a trial steering committee, including independent members and an independent data monitoring committee. Results will be published in a peer-reviewed journal and presented at international conferences.Trial registration number ISRCTN91927162; Pre-results.

Published
2016
Full Text
View/download PDF

16. MA06.07 Impact of Type 2 Diabetes Mellitus and Its Metabolic Control on Prognosis of Unresectable Non-Small Cell Lung Cancer Patients

Author

Sirvén, Milana Bergamino, primary, Rullan, Aj, additional, Saigi, Maria, additional, Peiró, Inmaculada, additional, Montanya, Eduard, additional, Palmero, Ramon, additional, Ruffinelli, Jose Carlos, additional, Navarro-Martin, Arturo, additional, Viñolas, Marta Domenech, additional, Franco, Ana Ortega, additional, Padrones, Susana, additional, Aso, Samantha, additional, Brao, Isabel, additional, Nadal, Ernest, additional, and Cardenal, Felipe, additional

Published
2017
Full Text
View/download PDF

17. P2.02-010 Prognosis Impact of Oligoprogression Following Definitive Chemo-Radiotherapy in Stage III Non-Small Cell Lung Cancer

Author

Saigi, Maria, primary, Rullan, Aj, additional, Sirvén, Milana Bergamino, additional, Navarro-Martin, Arturo, additional, Arnaiz, Ma Dolores, additional, Palmero, Ramon, additional, Plana, Maria, additional, Ruffinelli, Jose Carlos, additional, Mesia, Carles, additional, Padrones, Susana, additional, Aso, Samantha, additional, Brao, Isabel, additional, Arellano, Monica, additional, Saldaña, Joana, additional, Navarro, Valentin, additional, Cardenal, Felipe, additional, and Nadal, Ernest, additional

Published
2017
Full Text
View/download PDF

18. P2.03b-044 Treatment Outcome and the Role of Primary Tumor Therapy in a Cohort of Patients with Synchronous Oligometastatic NSCLC

Author

Ruffinelli, Jose Carlos, primary, Navarro-Martin, Arturo, additional, Doménech, Marta, additional, Palmero, Ramon, additional, Padrones, Susana, additional, Arnaiz, Ma Dolores, additional, Aso, Samantha, additional, Ramos, Ricard, additional, Macia, Ivan, additional, Plana, Maria, additional, Mesia, Carles, additional, Rivas, Francisco, additional, Andia, Eduard, additional, Conejero, Ariadna, additional, Vercher, Jose Luis, additional, Brao, Isabel, additional, Arellano, Monica, additional, Cardenal, Felipe, additional, and Nadal, Ernest, additional

Published
2017
Full Text
View/download PDF

20. P2.05-054 Radiation Pneumonitis; Early Diagnosis and Protein Expression Profile in NSCLC Patients

Author

Aso, Samantha, primary, Navarro-Martin, Arturo, additional, Padrones, Susana, additional, Cardenal, Felipe, additional, Cubero, Noelia, additional, Lopez-Lisbona, Rosa, additional, Arnaiz, Ma Dolores, additional, Palmero, Ramon, additional, Montes, Ana, additional, Nadal, Ernest, additional, Molina, Maria, additional, and Dorca, Jordi, additional

Published
2017
Full Text
View/download PDF

21. Protocol for the CONVERT trial—Concurrent ONce-daily VErsus twice-daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status

Author

Faivre-Finn, Corinne, primary, Falk, Sally, additional, Ashcroft, Linda, additional, Bewley, Michelle, additional, Lorigan, Paul, additional, Wilson, Elena, additional, Groom, Nicki, additional, Snee, Michael, additional, Fournel, Pierre, additional, Cardenal, Felipe, additional, Bezjak, Andrea, additional, and Blackhall, Fiona, additional

Published
2016
Full Text
View/download PDF

22. Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer

Author

Ajona, Daniel, primary, Razquin, Cristina, additional, Pastor, Maria Dolores, additional, Pajares, Maria Jose, additional, Garcia, Javier, additional, Cardenal, Felipe, additional, Fleischhacker, Michael, additional, Lozano, Maria Dolores, additional, Zulueta, Javier J., additional, Schmidt, Bernd, additional, Nadal, Ernest, additional, Paz-Ares, Luis, additional, Montuenga, Luis M., additional, and Pio, Ruben, additional

Published
2015
Full Text
View/download PDF

23. Epigenetic Inactivation of microRNA-34b/c Predicts Poor Disease-Free Survival in Early-Stage Lung Adenocarcinoma

Author

Nadal, Ernest, primary, Chen, Guoan, additional, Gallegos, Marc, additional, Lin, Lin, additional, Ferrer-Torres, Daysha, additional, Truini, Anna, additional, Wang, Zhuwen, additional, Lin, Jules, additional, Reddy, Rishindra M., additional, Llatjos, Roger, additional, Escobar, Ignacio, additional, Moya, Juan, additional, Chang, Andrew C., additional, Cardenal, Felipe, additional, Capellà, Gabriel, additional, and Beer, David G., additional

Published
2013
Full Text
View/download PDF

24. Protocol for the CONVERT trial -- Concurrent ONce-daily VErsus twice- daily RadioTherapy: an international 2-arm randomised controlled trial of concurrent chemoradiotherapy comparing twice-daily and once-aily radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status

Author

Faivre-Finn, Corinne, Falk, Sally, Ashcroft, Linda, Bewley, Michelle, Lorigan, Paul, Wilson, Elena, Groom, Nicki, Snee, Michael, Fournel, Pierre, Cardenal, Felipe, Bezjak, Andrea, and Blackhall, Fiona

Abstract

Introduction: Concurrent ONce-daily VErsus twicedaily RadioTherapy (CONVERT) is the only multicentre, international, randomised, phase III trial open in Europe and Canada looking at optimisation of chemoradiotherapy (RT) in limited stage small cell lung cancer (LS-SCLC). Following on from the Turrisi trial of once-daily versus twice-daily (BD) concurrent chemoradiotherapy, there is a real need for a new phase III trial using modern conformal RT techniques and investigating higher once-daily radiation dose. This trial has the potential to define a new standard chemo- RT regimen for patients with LS-SCLC and good performance status. Methods and analysis: 447 patients with histologically or cytologically proven diagnosis of SCLC were recruited from 74 centres in eight countries between 2008 and 2013. Patients were randomised to receive either concurrent twice-daily RT(45 Gy in 30 twice-daily fractions over 3 weeks) or concurrent oncedaily RT(66 Gy in 33 once-daily fractions over 6.5 weeks) both starting on day 22 of cycle 1. Patients are followed up until death. The primary end point of the study is overall survival and secondary end points include local progression-free survival, metastasis-free survival, acute and late toxicity based on the Common Terminology Criteria for Adverse Events V.3.0, chemotherapy and RTdose intensity. Ethics and dissemination: The trial received ethical approval from NRES Committee North West-Greater Manchester Central (07/H1008/229). There is a trial steering committee, including independent members and an independent data monitoring committee. Results will be published in a peer-reviewed journal and presented at international conferences [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

25. Abstract 4112: De novo EGFR T790M mutation modifies outcome to second-line erlotinib in non-small cell lung cancer (NSCLC) according to metastatic site and upfront chemotherapy

Author

Rosell, Rafael, primary, Molina, Miguel Angel, additional, Sanchez, Jose Javier, additional, Taron, Miquel, additional, Benlloch, Susana, additional, Moran, Teresa, additional, Carcereny, Enric, additional, Cardenal, Felipe, additional, Massuti, Bartomeu, additional, and Magri, Ignacio, additional

Published
2011
Full Text
View/download PDF

26. Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non–Small-Cell Lung Cancer Patients with EGFR Mutations

Author

Rosell, Rafael, primary, Molina, Miguel Angel, additional, Costa, Carlota, additional, Simonetti, Sara, additional, Gimenez-Capitan, Ana, additional, Bertran-Alamillo, Jordi, additional, Mayo, Clara, additional, Moran, Teresa, additional, Mendez, Pedro, additional, Cardenal, Felipe, additional, Isla, Dolores, additional, Provencio, Mariano, additional, Cobo, Manuel, additional, Insa, Amelia, additional, Garcia-Campelo, Rosario, additional, Reguart, Noemi, additional, Majem, Margarita, additional, Viteri, Santiago, additional, Carcereny, Enric, additional, Porta, Ruth, additional, Massuti, Bartomeu, additional, Queralt, Cristina, additional, de Aguirre, Itziar, additional, Sanchez, Jose Miguel, additional, Sanchez-Ronco, Maria, additional, Mate, Jose Luis, additional, Ariza, Aurelio, additional, Benlloch, Susana, additional, Sanchez, Jose Javier, additional, Bivona, Trever G, additional, Sawyers, Charles L, additional, and Taron, Miquel, additional

Published
2011
Full Text
View/download PDF

27. Complement Factor H Is Elevated in Bronchoalveolar Lavage Fluid and Sputum from Patients with Lung Cancer

Author

Pio, Ruben, primary, Garcia, Javier, additional, Corrales, Leticia, additional, Ajona, Daniel, additional, Fleischhacker, Michael, additional, Pajares, Maria J., additional, Cardenal, Felipe, additional, Seijo, Luis, additional, Zulueta, Javier J., additional, Nadal, Ernest, additional, Witt, Christian, additional, Lozano, Maria D., additional, Schmidt, Bernd, additional, and Montuenga, Luis M., additional

Published
2010
Full Text
View/download PDF

28. B5-06: Mature results of PulmonArt: Involved-field 3D radiotherapy (RT) and docetaxel/cisplatin chemotherapy (CT) in a randomised phase 2 study comparing concurrent CT-RT followed by consolidation CT, with induction CT followed by concurrent CT-RT in patients (pts) with stage III non-small cell lung cancer (NSCLC)

Author

Van Meerbeeck, Jan P., primary, Cardenal, Felipe, additional, Vansteenkiste, Johan, additional, Stigt, Jos, additional, Akyol, Fadil, additional, De Neve, Wilfried, additional, Bakker, Joke, additional, Dupont, Jean Michel, additional, Scagliotti, Giorgio V., additional, and Senan, Suresh, additional

Published
2007
Full Text
View/download PDF

29. PD4-2-7: Non-small cell lung cancer in the elderly

Author

Provencio, Mariano, primary, Camps, Carlos, additional, Cantos, Blanca, additional, Alberola, Vicente, additional, Domine, Manuel, additional, Isla, Dolores, additional, Millan, Isabel, additional, Massutí, Bartomeu, additional, Cardenal, Felipe, additional, and Rosell, Rafael, additional

Published
2007
Full Text
View/download PDF

30. P2-092: 14-3-3 sigma and checkpoint with forkhead and ring finger (CHFR) methylation in serum in erlotinib-treated non-small-cell lung cancer (NSCLC) patients (p) with EGFR mutations

Author

Reguart, Noemi, primary, Porta, Rut, additional, Cantos, Blanca, additional, Cardenal, Felipe, additional, Cuello, Mauricio, additional, Lianes, Pilar, additional, Majem, Margarita, additional, Massuti, Bartomeu, additional, Taron, Miguel, additional, and Rosell, Rafael, additional

Published
2007
Full Text
View/download PDF

32. Mature results of PulmonArt: Involved-field 3D radiotherapy (RT) and docetaxel/cisplatin chemotherapy (CT) in a randomised phase 2 study comparing concurrent CT-RT followed by consolidation CT, with induction CT followed by concurrent CT-RT in patients (pts) with stage III non-small cell lung cancer (NSCLC)

Author

Van Meerbeeck, Jan P., Cardenal, Felipe, Vansteenkiste, Johan, Stigt, Jos, Akyol, Fadil, De Neve, Wilfried, Bakker, Joke, Dupont, Jean Michel, Scagliotti, Giorgio V., and Senan, Suresh

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results